Novel choline analog 2-(4-((1-phenyl-1H-pyrazol-4-yl)methyl)piperazin-1-yl)ethan-1-ol produces sympathoinhibition, hypotension, and antihypertensive effects
- 161 Downloads
The search for new drugs remains an important focus for the safe and effective treatment of cardiovascular diseases. Previous evidence has shown that choline analogs can offer therapeutic benefit for cardiovascular complications. The current study investigates the effects of 2-(4-((1-phenyl-1H-pyrazol-4-yl)methyl)piperazin-1-yl)ethan-1-ol (LQFM032) on cardiovascular function and cholinergic-nitric oxide signaling. Synthesized LQFM032 (0.3, 0.6, or 1.2 mg/kg) was administered by intravenous and intracerebroventricular routes to evaluate the potential alteration of mean arterial pressure, heart rate, and renal sympathetic nerve activity of normotensive and hypertensive rats. Vascular function was further evaluated in isolated vessels, while pharmacological antagonists and computational studies of nitric oxide synthase and muscarinic receptors were performed to assess possible mechanisms of LQFM032 activity. The intravenous and intracerebroventricular administration of LQFM032 elicited a temporal reduction in mean arterial pressure, heart rate, and renal sympathetic nerve activity of rats. The cumulative addition of LQFM032 to isolated endothelium-intact aortic rings reduced vascular tension and elicited a concentration-dependent relaxation. Intravenous pretreatment with L-NAME (nitric oxide synthase inhibitor), atropine (nonselective muscarinic receptor antagonist), pirenzepine, and 4-DAMP (muscarinic M1 and M3 subtype receptor antagonist, respectively) attenuated the cardiovascular effects of LQFM032. These changes may be due to a direct regulation of muscarinic signaling as docking data shows an interaction of choline analog with M1 and M3 but not nitric oxide synthase. Together, these findings demonstrate sympathoinhibitory, hypotensive, and antihypertensive effects of LQFM032 and suggest the involvement of muscarinic receptors.
KeywordsCholine analog Muscarinic receptor Nitric oxide synthase Sympathoinhibition
This work was supported by CAPES, CNPq, FAPEG and FUNDECT. Osmar N. Silva holds a postdoctoral scholarship from the National Council of Technological and Scientific Development (CNPq) and Fundação de Apoio ao Desenvolvimento do Ensino, Ciência e Tecnologia do Estado de Mato Grosso do Sul (FUNDECT) – Brazil [300583/2016-8]. We thank Marcelo Rodrigues Martins (PhD) of the veterinary pharmacy section Universidade Federal de Goiás for providing anesthetics freely.
JOF, NMA and GRP: synthesis and chemical characterization of LQFM032. BV and HV: in silico assays. JOF, CHX, CHC, ONS, OLF, IOS: devising the research method/methodology used. AAM, EAC, CHX, CHC, GRP: conducting research, statistical analysis and calculations. RM, FSC, LML: devising the concept and assumptions of the article. All authors wrote the manuscript. All authors read and approved the manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures were performed in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals and were approved by the Ethics Committee of the Federal University of Goiás (protocol #172/09) as compliant with Brazil law.
- Borella TL, De Luca LA, Colombari DSA, Menani JV (2008) Central muscarinic receptor subtypes involved in pilocarpine-induced salivation, hypertension and water intake. Br J Pharmacol. https://doi.org/10.1038/bjp.2008.355
- Buccafusco JJ (1996) The role of central cholinergic neurons in the regulation of blood pressure and in experimental hypertension. Pharmacol Rev 48:179–211Google Scholar
- De Oliveira-Sales EB, Nishi EE, Boim MA et al (2010) Upregulation of AT1R and iNOS in the rostral ventrolateral medulla (RVLM) is essential for the sympathetic hyperactivity and hypertension in the 2K-1C Wistar rat model. Am J Hypertens 23:708–715. https://doi.org/10.1038/ajh.2010.64 CrossRefGoogle Scholar
- DeLano WL (2002) The PyMOL Molecular Graphics System. Schrödinger LLC wwwpymolorg Version 1. http://www.pymol.org
- Grassi G, Quarti-Trevano F, Seravalle G et al (2011) Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension 57:846–851. https://doi.org/10.1161/HYPERTENSIONAHA.110.164780 CrossRefGoogle Scholar
- Höglund AU, Baghdoyan HA (1997) M2, M3 and M4, but not M1, muscarinic receptor subtypes are present in rat spinal cord. J Pharmacol Exp Ther 281:470–477Google Scholar
- Li P, Sun HJ, Cui BP et al (2013) Angiotensin-(1-7) in the rostral ventrolateral medulla modulates enhanced cardiac sympathetic afferent reflex and sympathetic activation in renovascular hypertensive rats. Hypertension 61:820–827. https://doi.org/10.1161/HYPERTENSIONAHA.111.00191 CrossRefGoogle Scholar
- Lundin S, Rickstein S, Thoren P (1984) Renal sympathetic activity in spontaneously hypertensive rats and normotensive controls, as studied by three different methods. Acta Physiol Scand 120:265–272. https://doi.org/10.1111/j.1748-1716.1984.tb00133.x CrossRefGoogle Scholar
- Moreira TS, Takakura AC, Sato MA et al (2006) Antihypertensive responses elicited by central moxonidine in rats: possible role of nitric oxide. J Cardiovasc Pharmacol 47:780–787. https://doi.org/10.1097/01.fjc.0000211794.68152.04 CrossRefGoogle Scholar
- Mourão AA, de Mello ABS, Dos Santos Moreira MC et al (2018) Median preoptic nucleus excitatory neurotransmitters in the maintenance of hypertensive state. Brain Res Bull 142:207–215. https://doi.org/10.1016/j.brainresbull.2018.06.011 CrossRefGoogle Scholar
- Paxinos G, Watson C (1998) The Rat Brain in Stereotaxic Coordinates. Academic Press, San DiegoGoogle Scholar
- Pediani JD, Ward RJ, Godin AG et al (2016) Dynamic regulation of quaternary organization of the m1 muscarinic receptor by subtype-selective antagonist drugs. J Biol Chem. https://doi.org/10.1074/jbc.M115.712562
- Penne EL, Neumann J, Klein IH et al (2009) Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment. J Nephrol 22:208–215Google Scholar
- Pinto IS, Mourão AA, da Silva EF et al (2016) Blockade of rostral ventrolateral medulla (RVLM) Bombesin receptor type 1 decreases blood pressure and sympathetic activity in anesthetized spontaneously hypertensive rats. Front Physiol 7:205. https://doi.org/10.3389/fphys.2016.00205 CrossRefGoogle Scholar
- Schlaich MP, Lambert E, Kaye DM et al (2004) Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and angiotensin neuromodulation. Hypertension 43:169–175. https://doi.org/10.1161/01.HYP.0000103160.35395.9E CrossRefGoogle Scholar
- Sundaram K, Krieger AJ, Sapru H (1988) M2 muscarinic receptors mediate pressor responses to cholinergic agonists in the ventrolateral medullary pressor area. Brain Res. https://doi.org/10.1016/0006-8993(88)91032-3
- Yalcin M, Cavun S, Yilmaz MS, Savci V (2005) The involvement of central cholinergic system in the pressor effect of intracerebroventricularly injected U-46619, a thromboxane A2 analog, in conscious normotensive rats. Naunyn Schmiedeberg's Arch Pharmacol 372:31–40. https://doi.org/10.1007/s00210-005-1087-x CrossRefGoogle Scholar